KPIs & Operating Metrics(New)
Breakdown Of AssetsCapital CommitmentsCollaboration Revenue By CategoryCollaboration Revenue By Category AnnualContractual ObligationsDeferred RevenueEmployee StatisticsGross ProfitIncome (Loss) Before Income TaxNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue By CategoryProduct Revenue By Category AnnualProperty And Equipment, Net BreakdownPurchase CommitmentsRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Gross Profit (2017 - 2025)

BeOne Medicines (ONC) has disclosed Gross Profit for 9 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 40.16% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 billion, a 45.34% increase, with the full-year FY2025 number at $4.7 billion, up 45.34% from a year prior.
  • Gross Profit was $1.4 billion for Q4 2025 at BeOne Medicines, up from $1.2 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.4 billion in Q4 2025 to a low of $113.7 million in Q2 2021.
  • A 5-year average of $605.5 million and a median of $550.9 million in 2021 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: soared 1411.97% in 2021, then tumbled 57.89% in 2022.
  • BeOne Medicines' Gross Profit stood at $165.4 million in 2021, then surged by 85.31% to $306.6 million in 2022, then skyrocketed by 72.41% to $528.6 million in 2023, then surged by 82.99% to $967.3 million in 2024, then soared by 40.16% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Gross Profit are $1.4 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).